US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

REIN THERAPEUTICS INC

1.11

-0.0450-3.90%

Post-market: 1.110.00000.00%16:10 EDT

Volume:37.08K

Turnover:42.74K

Market Cap:25.58M

PE:-0.39

High:1.16

Open:1.16

Low:1.10

Close:1.16

Loading ...

Overview Company News Filings

Rein Therapeutics Inc. Secures $6 Million Pre-Paid Advance Financing Agreement with Yorkville

Rein Therapeutics enters agreements for up to $21M in financing

Rein Therapeutics Inc - Proceeds to Support Renew Phase 2 Trial of Lti-03 for Ipf

THOMSON REUTERS

Rein Therapeutics Enters into Agreements for up to $21 Million in Flexible Financing

Rein Therapeutics Amends Bylaws to Set Quorum at 40% for Shareholder Meetings

Shareholder Activism Rises as Rein Therapeutics Adjourns Annual Meeting to July 23

Top Premarket Decliners

MT Newswires Live

Rein Therapeutics pauses dosing in lung disease trial after US FDA places hold

Rein Therapeutics Pauses U.S. Enrollment for Phase 2 RENEW Trial of LTI-03, Continues in Australia, UK, and Europe

BRIEF-Rein Therapeutics Announces First Patient Dosed In Renew Phase 2 Trial Of Lti-03 In Patients With Ipf

Rein Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Rein Therapeutics Reports Q1 2025 Financial Results: Cash Position Declines, R&D and G&A Expenses Decrease

Press Release: Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Rein Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview

Rein Therapeutics Announces Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis with Advanced AI Integration

Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF

Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference

BRIEF-Rein Therapeutics Granted Two Patents Covering The Novel Formulation And Administration Methods Of Dry Powder LTI-03 For Treatment Of Respiratory Diseases

Rein Therapeutics’ LTI-2355 peptide shows therapuetic potential in study

Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/RNTX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RNTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RNTX\",,,,,undefined,":{"symbol":"RNTX","market":"US","secType":"STK","nameCN":"REIN THERAPEUTICS INC","latestPrice":1.11,"timestamp":1754596800000,"preClose":1.155,"halted":0,"volume":37080,"hourTrading":{"tag":"盘后","latestPrice":1.11,"preClose":1.11,"latestTime":"16:10 EDT","volume":1,"amount":1.11,"timestamp":1754597404054},"delay":0,"floatShares":19395868,"shares":23046121,"eps":-2.870855,"marketStatus":"Post-Mkt","change":-0.045,"latestTime":"08-07 17:36:33 EDT","open":1.16,"high":1.16,"low":1.1,"amount":42736.5138,"amplitude":0.051948,"askPrice":1.35,"askSize":100,"bidPrice":1.01,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-2.870855,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1754611200000},"marketStatusCode":4,"adr":0,"listingDate":1498708800000,"exchange":"NASDAQ","adjPreClose":1.155,"preHourTrading":{"tag":"盘前","latestPrice":1.25,"preClose":1.13,"latestTime":"09:25 EDT","volume":9961,"amount":12065.629807,"timestamp":1754573128439},"postHourTrading":{"tag":"盘后","latestPrice":1.11,"preClose":1.11,"latestTime":"16:10 EDT","volume":1,"amount":1.11,"timestamp":1754597404054},"volumeRatio":0.299293},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RNTX\",,,,,undefined,":{"symbol":"RNTX","floatShares":19395868,"roa":"-21.14%","roe":"-86.78%","lyrEps":-3.505399,"volumeRatio":0.299293,"shares":23046121,"dividePrice":0,"high":1.16,"amplitude":0.051948,"preClose":1.155,"low":1.1,"week52Low":1.04,"pbRate":"5.25","week52High":4.4,"institutionHeld":0,"latestPrice":1.11,"committee":0.333333,"eps":-2.870855,"divideRate":0,"volume":37080,"delay":0,"ttmEps":-2.870855,"open":1.16,"prevYearClose":2.3,"prevWeekClose":1.11,"prevMonthClose":1.165,"prevQuarterClose":1.4,"fiveDayClose":1.165,"twentyDayClose":1.48,"sixtyDayClose":1.8},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RNTX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2555044095","title":"Rein Therapeutics Inc. Secures $6 Million Pre-Paid Advance Financing Agreement with Yorkville","url":"https://stock-news.laohu8.com/highlight/detail?id=2555044095","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555044095?lang=en_us&edition=fundamental","pubTime":"2025-07-30 21:05","pubTimestamp":1753880724,"startTime":"0","endTime":"0","summary":"Rein Therapeutics Inc. has entered into a new financing agreement with YA II PN, Ltd., a Cayman Islands exempt limited partnership managed by Yorkville. The agreement, known as the Pre-Paid Advance Agreement , was executed on July 29, 2025. Under the terms of the PPA, Rein Therapeutics can request pre-paid advances from Yorkville totaling up to $6.0 million over a 12-month period, subject to specific conditions. Yorkville purchased an initial advance of $1.0 million on the effective date for net proceeds of $0.95 million. The financing arrangement is designed to support Rein Therapeutics' financial operations and growth initiatives.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. published the original content use","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250730:nNDL1GMFyj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNTX","BK4139"],"gpt_icon":0},{"id":"2555041217","title":"Rein Therapeutics enters agreements for up to $21M in financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2555041217","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555041217?lang=en_us&edition=fundamental","pubTime":"2025-07-30 20:36","pubTimestamp":1753878962,"startTime":"0","endTime":"0","summary":"Rein Therapeutics (RNTX) entered into two strategic financing agreements with an affiliate of Yorkville Advisors Global, LP, providing the potentia...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rein-therapeutics-enters-agreements-for-up-to-21m-in-financing-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rein-therapeutics-enters-agreements-for-up-to-21m-in-financing-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNTX","LENZ","BK4007","BK4539","BK4139"],"gpt_icon":0},{"id":"2555041487","title":"Rein Therapeutics Inc - Proceeds to Support Renew Phase 2 Trial of Lti-03 for Ipf","url":"https://stock-news.laohu8.com/highlight/detail?id=2555041487","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555041487?lang=en_us&edition=fundamental","pubTime":"2025-07-30 20:30","pubTimestamp":1753878601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250730:nTUA2JNQML:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RNTX"],"gpt_icon":0},{"id":"2555445210","title":"Rein Therapeutics Enters into Agreements for up to $21 Million in Flexible Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2555445210","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555445210?lang=en_us&edition=fundamental","pubTime":"2025-07-30 20:30","pubTimestamp":1753878600,"startTime":"0","endTime":"0","summary":"- Financing designed to support Phase 2 IPF trial and pipeline advancementAUSTIN, Texas, July  30, 2025  (GLOBE NEWSWIRE) -- Rein Therapeutics(\"Rein\") (NASDAQ: RNTX), a biopharmaceutical company advan","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/30/3124071/28652/en/Rein-Therapeutics-Enters-into-Agreements-for-up-to-21-Million-in-Flexible-Financing.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4539","BK4139","BK4007","SEPA","RNTX"],"gpt_icon":0},{"id":"2550695989","title":"Rein Therapeutics Amends Bylaws to Set Quorum at 40% for Shareholder Meetings","url":"https://stock-news.laohu8.com/highlight/detail?id=2550695989","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550695989?lang=en_us&edition=fundamental","pubTime":"2025-07-12 04:02","pubTimestamp":1752264120,"startTime":"0","endTime":"0","summary":"Rein Therapeutics Inc. announced that its Board of Directors approved an amendment to the company's Amended and Restated By-laws. The amendment, effective immediately, specifies that a quorum at all stockholder meetings will require forty percent of the shares of capital stock issued and outstanding and entitled to vote, whether present in person, by remote communication, or represented by proxy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 11, 2025, and is solely responsible for the information contained therei","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250711:nNDL29ck94:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RNTX"],"gpt_icon":0},{"id":"2545423589","title":"Shareholder Activism Rises as Rein Therapeutics Adjourns Annual Meeting to July 23","url":"https://stock-news.laohu8.com/highlight/detail?id=2545423589","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545423589?lang=en_us&edition=fundamental","pubTime":"2025-06-24 22:11","pubTimestamp":1750774304,"startTime":"0","endTime":"0","summary":"Rein Therapeutics Inc. recently announced the adjournment of its 2025 annual meeting of stockholders, originally scheduled for June 24, 2025, due to the lack of a quorum. The meeting has been rescheduled to July 23, 2025, and will be held virtually. Rein Therapeutics, a biopharmaceutical company focused on developing medications for orphan pulmonary and fibrosis indications, is encouraging stockholders to participate and vote on the proposals detailed in their definitive proxy statement. The board of directors, led by Chairperson [First Name] [Last Name], is urging stockholders to vote in favor of all proposals. Proxies submitted prior to the adjournment will remain valid unless revoked or amended by stockholders. Voting can be modified via signed proxy or electronically until July 22, 2025. The meeting will be accessible online, providing an opportunity for shareholders to engage and cast their votes.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250624:nNDL4BpxqM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNTX","BK4139"],"gpt_icon":0},{"id":"2543841726","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2543841726","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543841726?lang=en_us&edition=fundamental","pubTime":"2025-06-13 20:21","pubTimestamp":1749817291,"startTime":"0","endTime":"0","summary":"SharpLink Gaming  shares fell more than 67% in recent Friday premarket activity, a day after the company announced a $462 million acquisition of ether . It also said it raised $79 million in gross proceeds through its at-the-market facility, with the majority targeted at additional purchases of ETH.Rein Therapeutics  stock fell 15%, a day after the company said in a regulatory filing it paused enrollment and patient dosing for its phase 2 Renew study of LTI-03 at its clinical sites in the US.Oklo  shares slipped 6.7% after the company said Thursday it priced a public offering of about 6.7 million class A common shares at $60 apiece for gross proceeds of roughly $400 million.BHP Group  stock slid more than 2% after Argus downgraded the mining company to hold from buy.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BHP.AU","BK7511","BK4606","BK4588","BK4539","RNTX","SBET","BK4150","BK4585","BK7095","LU0300736492.USD","ETH","BHP","BK7507","BK4601","BK4168","BK4139","BK4081"],"gpt_icon":1},{"id":"2543954759","title":"Rein Therapeutics pauses dosing in lung disease trial after US FDA places hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2543954759","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543954759?lang=en_us&edition=fundamental","pubTime":"2025-06-13 04:34","pubTimestamp":1749760484,"startTime":"0","endTime":"0","summary":"Rein Therapeutics pauses dosing in lung disease trial after US FDA places holdJune 12  - Rein Therapeutics RNTX.O said on Thursday it has paused enrollment and patient dosing in the U.S. after the Food and Drug Administration placed a clinical hold on a mid-stage trial of its lung disease drug.   ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250612:nL4N3SF1EJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RNTX"],"gpt_icon":0},{"id":"2543954209","title":"Rein Therapeutics Pauses U.S. Enrollment for Phase 2 RENEW Trial of LTI-03, Continues in Australia, UK, and Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2543954209","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543954209?lang=en_us&edition=fundamental","pubTime":"2025-06-13 04:25","pubTimestamp":1749759935,"startTime":"0","endTime":"0","summary":"Rein Therapeutics Inc. has announced a pause in enrollment and patient dosing in its Phase 2 RENEW trial for the investigational drug LTI-03 at clinical trial sites in the United States. The pause, instituted on June 10, 2025, follows a clinical hold placed by the U.S. Food and Drug Administration  as the company works to address non-clinical requests from the agency. Despite the pause in the U.S., the RENEW trial continues to progress with site initiation and patient enrollment in Australia, the United Kingdom, and Europe. LTI-03 is being developed as a treatment for idiopathic pulmonary fibrosis , and previous Phase 1b clinical trial results indicated positive topline data with no safety signals observed. No drug-related serious adverse events have been reported in any of the studies involving LTI-03 to date.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250612:nNDLbpHFq4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNTX","BK4139"],"gpt_icon":0},{"id":"2538663944","title":"BRIEF-Rein Therapeutics Announces First Patient Dosed In Renew Phase 2 Trial Of Lti-03 In Patients With Ipf","url":"https://stock-news.laohu8.com/highlight/detail?id=2538663944","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538663944?lang=en_us&edition=fundamental","pubTime":"2025-05-27 20:09","pubTimestamp":1748347767,"startTime":"0","endTime":"0","summary":"BRIEF-Rein Therapeutics Announces First Patient Dosed In Renew Phase 2 Trial Of Lti-03 In Patients With IpfMay 27  - REIN THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN RENEW PHASE 2 TRIAL OF LTI-03 IN PATIENTS WITH IPFREIN THERAPEUTICS INC: TOPLINE INTERIM DATA FROM RENEW IS EXPECTED IN FIRST HALF OF 2026Source text: ID:nPn15f7lca ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nTUA8R8VNC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1791710400.SGD","LU0648001328.SGD","RNTX","LU1201861249.SGD","LU0198837287.USD","LU1989764664.SGD","LU0882574055.USD","BK4588","LU1989764748.USD","BK4121","LU0477156797.USD","LU1201861165.SGD","LU0130518102.USD","LU0130102774.USD","LU0648000940.SGD","BK4585","BK4530","LU0477156953.USD","LU0528227936.USD","LU1261432733.SGD","LU0130517989.USD","LU1791710582.SGD","LU0130103400.USD","BK4139","IQV","LU0980610538.SGD"],"gpt_icon":0},{"id":"2535166351","title":"Rein Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2535166351","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535166351?lang=en_us&edition=fundamental","pubTime":"2025-05-16 16:03","pubTimestamp":1747382587,"startTime":"0","endTime":"0","summary":"Rein Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryRein Therapeutics Inc RNTX.OQ reported a quarterly adjusted loss of 25 cents per share for the quarter ended Marc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250516:nL8N3RO0EL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNTX"],"gpt_icon":0},{"id":"2535870174","title":"Rein Therapeutics Reports Q1 2025 Financial Results: Cash Position Declines, R&D and G&A Expenses Decrease","url":"https://stock-news.laohu8.com/highlight/detail?id=2535870174","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535870174?lang=en_us&edition=fundamental","pubTime":"2025-05-16 04:15","pubTimestamp":1747340111,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on May 15, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nNDLbVnsHM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNTX","BK4139"],"gpt_icon":0},{"id":"2535108870","title":"Press Release: Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2535108870","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535108870?lang=en_us&edition=fundamental","pubTime":"2025-05-16 04:09","pubTimestamp":1747339740,"startTime":"0","endTime":"0","summary":"RENEW Phase 2 trial evaluating the safety, tolerability, and efficacy of LTI-03 in idiopathic pulmonary fibrosis  initiated with topline interim data expected in the first half of 2026. Two abstracts accepted to the American Thoracic Society  2025 International Conference. Cash runway extended following previously announced warrant transactions and private placement. \"Rein has completed a multitude of key accomplishments since the beginning of the year, and we are particularly excited to have initiated the Phase 2 RENEW trial of LTI-03 in patients with IPF,\" said Brian Windsor, Ph.D., President and Chief Executive Officer of Rein Therapeutics. \"We have taken several strategic steps to prepare for this trial. Our LTI-03 program continues to evolve as we entered into a collaboration with Qureight to bring cutting-edge technology to our imaging and data analysis and obtained patents covering our novel formulation and administration methods. We are committed to continuing this momentum of ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4161","ATS","BK4539","CSD","RNTX","BK4139","BK4007"],"gpt_icon":0},{"id":"2534667644","title":"Rein Therapeutics Inc  expected to post a loss of 24 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2534667644","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534667644?lang=en_us&edition=fundamental","pubTime":"2025-05-10 05:46","pubTimestamp":1746827165,"startTime":"0","endTime":"0","summary":"Rein Therapeutics Inc  expected to post a loss of24cents a share - Earnings Preview Rein Therapeutics Inc RNTX.OQ RNTX.O is expected to show no change in quarterly revenue when it reports  results on ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250509:nL8N3RH3HY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNTX"],"gpt_icon":0},{"id":"2532075065","title":"Rein Therapeutics Announces Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis with Advanced AI Integration","url":"https://stock-news.laohu8.com/highlight/detail?id=2532075065","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532075065?lang=en_us&edition=fundamental","pubTime":"2025-05-01 19:01","pubTimestamp":1746097310,"startTime":"0","endTime":"0","summary":"Rein Therapeutics Inc. has announced a collaboration with Qureight Ltd to integrate deep-learning technology into their upcoming Phase 2 clinical trial of LTI-03, aimed at treating idiopathic pulmonary fibrosis . This partnership will leverage Qureight's advanced AI imaging platform to provide detailed insights into the effects of LTI-03 on lung structure and function. The Phase 2 trial will assess the safety, tolerability, and activity of LTI-03 across multiple biomarkers, as well as its potential for promoting healthy tissue regeneration. Rein Therapeutics previously reported positive results from their Phase 1b trial, showing promising trends in biomarker response. Further details about the Phase 2 trial design are expected to be announced soon.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should n","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250501:nNDLc0nR6g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RNTX"],"gpt_icon":0},{"id":"2532075868","title":"Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF","url":"https://stock-news.laohu8.com/highlight/detail?id=2532075868","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532075868?lang=en_us&edition=fundamental","pubTime":"2025-05-01 19:00","pubTimestamp":1746097200,"startTime":"0","endTime":"0","summary":"AUSTIN, Texas, May 1, 2025 /PRNewswire/ -- Rein Therapeutics  , a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, and Qureight Ltd, a Core Imaging Laboratory developing deep-learning image analytics, today announced a collaboration for the integration of Qureight's deep-learning platform into Rein's planned Phase 2 trial of its lead asset LTI-03, a novel, multi-pathway, Caveolin-1-related peptide, for the treatment of idiopathic pulmonary fibrosis .Dr. Muhunthan Thillai, Chief Executive Officer of Qureight, said, \"We're delighted that our core platform and AI technology will be supporting Rein Therapeutics in advancing its treatment, LTI-03, for patients with IPF. Our AI tools will provide precise, quantitative insights into","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/rein-therapeutics-qureight-ltd-announce-110000614.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rein-therapeutics-qureight-ltd-announce-110000614.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","RNTX","LENZ","CSD","BK4139"],"gpt_icon":0},{"id":"2530472503","title":"Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2530472503","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530472503?lang=en_us&edition=fundamental","pubTime":"2025-04-28 19:00","pubTimestamp":1745838000,"startTime":"0","endTime":"0","summary":"AUSTIN, Texas, April 28, 2025 /PRNewswire/ --Rein Therapeutics  , a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications,today announced that an abstract has been accepted at the American Thoracic Society  2025 International Conference taking place May 18-21, 2025 in San Francisco, CA.Details of the poster presentation are as follows:. Presentation Title: Evaluating Alveolar Regenerative Properties of Caveolin Scaffolding Peptides  in Three Dimensional  Alveolospheres from IPF and Normal Donor Lung Samples Poster #: P1463Session: B75 Targeting Cellular Senescence, Immune Dysregulation, and Metabolism in Lung Injury and FibrosisDate & Time: Monday, May 19, 2025, at 11:30 AM PT/ 2:30 PM ET. Rein Investor Relations & Media Contact:Argot Partnersrein@argotpartners.com 212-600-1902","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/rein-therapeutics-announces-abstract-accepted-110000640.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rein-therapeutics-announces-abstract-accepted-110000640.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4161","BK4117","LENZ","RNTX","CSD","BK4139","BK4107","ATS","AFG"],"gpt_icon":0},{"id":"2529550541","title":"BRIEF-Rein Therapeutics Granted Two Patents Covering The Novel Formulation And Administration Methods Of Dry Powder LTI-03 For Treatment Of Respiratory Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2529550541","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529550541?lang=en_us&edition=fundamental","pubTime":"2025-04-23 19:05","pubTimestamp":1745406317,"startTime":"0","endTime":"0","summary":"BRIEF-Rein Therapeutics Granted Two Patents Covering The Novel Formulation And Administration Methods Of Dry Powder LTI-03 For Treatment Of Respiratory DiseasesApril 23 (Reuters) - Rein Therapeutics I","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nTUA9V95FF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RNTX"],"gpt_icon":0},{"id":"2527491244","title":"Rein Therapeutics’ LTI-2355 peptide shows therapuetic potential in study","url":"https://stock-news.laohu8.com/highlight/detail?id=2527491244","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527491244?lang=en_us&edition=fundamental","pubTime":"2025-04-15 19:11","pubTimestamp":1744715464,"startTime":"0","endTime":"0","summary":"Rein Therapeutics (RNTX) announced a publication highlighting the therapeutic potential of Caveolin-1-related peptide LTI-2355 in Idiopathic Pulmon...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rein-therapeutics-lti-2355-peptide-shows-therapuetic-potential-in-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rein-therapeutics-lti-2355-peptide-shows-therapuetic-potential-in-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","BK4007","RNTX"],"gpt_icon":0},{"id":"2527991034","title":"Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F","url":"https://stock-news.laohu8.com/highlight/detail?id=2527991034","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527991034?lang=en_us&edition=fundamental","pubTime":"2025-04-15 19:00","pubTimestamp":1744714800,"startTime":"0","endTime":"0","summary":"Manuscript highlights the effects of caveolin scaffolding domain peptide LTI-2355 on myeloid cell activity in Idiopathic Pulmonary Fibrosis  and Post-Acute Sequelae of COVID Fibrosis . AUSTIN, Texas, April 15, 2025 /PRNewswire/ --Rein Therapeutics  , a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced a publication highlighting the therapeutic potential of Caveolin-1-related peptide LTI-2355 in Idiopathic Pulmonary Fibrosis  and Post-Acute Sequelae of COVID Fibrosis  in the peer-reviewed journal, Biomedicines.Rein Therapeuticsis a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indica","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/rein-therapeutics-announces-publication-biomedicines-110000178.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rein-therapeutics-announces-publication-biomedicines-110000178.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","RNTX","CSD","BK4139","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":21,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RNTX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-15","symbol":"RNTX","fiscalQuarterEnding":"2025/03","expectedEps":-0.21,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"post","actualEps":-0.25},{"market":"US","date":"2025-04-07","symbol":"RNTX","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1743998400000,"reportTimeType":"post","actualEps":-0.26},{"market":"US","date":"2024-11-14","symbol":"RNTX","fiscalQuarterEnding":"2024/09","expectedEps":-0.25,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":-0.27},{"market":"US","date":"2024-08-14","symbol":"RNTX","fiscalQuarterEnding":"2024/06","expectedEps":-0.25,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"post","actualEps":-0.45},{"market":"US","date":"2024-05-15","symbol":"RNTX","fiscalQuarterEnding":"2024/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715745600000,"reportTimeType":"post","actualEps":-0.86}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RNTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RNTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1717214400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/RNTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"RNTX","date":"2025-08-06","current":-0.443838,"percent":0.978571,"low":-2.000549,"twenty":-1.496707,"median":-0.705061,"eighty":-0.54597,"high":-0.401342,"avg":-0.984645,"sd":0.479082,"marketCap":27194422},"quantilePoints":[{"date":"2025-01-17","current":-1.459659,"twenty":-1.48337,"median":-1.467068,"eighty":-1.447804,"marketCap":42681903},{"date":"2025-01-24","current":-1.630077,"twenty":-1.576729,"median":-1.478183,"eighty":-1.446322,"marketCap":47665070},{"date":"2025-01-31","current":-1.467069,"twenty":-1.741219,"median":-1.496707,"eighty":-1.462623,"marketCap":42898563},{"date":"2025-02-07","current":-1.704171,"twenty":-1.704171,"median":-1.526344,"eighty":-1.459659,"marketCap":49831664},{"date":"2025-02-14","current":-1.741218,"twenty":-1.704171,"median":-1.578211,"eighty":-1.462623,"marketCap":50914961},{"date":"2025-02-21","current":-1.98573,"twenty":-1.794566,"median":-1.630077,"eighty":-1.468551,"marketCap":58064721},{"date":"2025-02-28","current":-1.533754,"twenty":-1.79753,"median":-1.630077,"eighty":-1.47596,"marketCap":44848497},{"date":"2025-03-07","current":-1.467069,"twenty":-1.753073,"median":-1.607848,"eighty":-1.468551,"marketCap":42898563},{"date":"2025-03-14","current":-1.496707,"twenty":-1.741218,"median":-1.552277,"eighty":-1.467069,"marketCap":43765200},{"date":"2025-03-21","current":-1.430022,"twenty":-1.733809,"median":-1.518935,"eighty":-1.461141,"marketCap":41815266},{"date":"2025-03-28","current":-1.311471,"twenty":-1.704171,"median":-1.507821,"eighty":-1.431504,"marketCap":38348715},{"date":"2025-04-04","current":-1.259605,"twenty":-1.704171,"median":-1.496707,"eighty":-1.416685,"marketCap":36832099},{"date":"2025-04-11","current":-0.545587,"twenty":-1.696762,"median":-1.481888,"eighty":-1.32629,"marketCap":34308123},{"date":"2025-04-17","current":-0.577063,"twenty":-1.667124,"median":-1.474478,"eighty":-1.296652,"marketCap":36287438},{"date":"2025-04-25","current":-0.640015,"twenty":-1.630077,"median":-1.467069,"eighty":-1.259605,"marketCap":40246068},{"date":"2025-05-02","current":-0.573565,"twenty":-1.630077,"median":-1.459659,"eighty":-0.64701,"marketCap":36067514},{"date":"2025-05-09","current":-0.601544,"twenty":-1.630077,"median":-1.437431,"eighty":-0.622528,"marketCap":37826905},{"date":"2025-05-16","current":-0.825375,"twenty":-1.622667,"median":-1.430022,"eighty":-0.622528,"marketCap":51902033},{"date":"2025-05-23","current":-0.696336,"twenty":-1.607848,"median":-1.415203,"eighty":-0.629523,"marketCap":42665230},{"date":"2025-05-30","current":-0.696336,"twenty":-1.584138,"median":-1.407793,"eighty":-0.629523,"marketCap":42665230},{"date":"2025-06-06","current":-0.705061,"twenty":-1.560428,"median":-1.311471,"eighty":-0.635119,"marketCap":43199785},{"date":"2025-06-13","current":-0.712292,"twenty":-1.550055,"median":-1.296652,"eighty":-0.639316,"marketCap":43642859},{"date":"2025-06-20","current":-0.592974,"twenty":-1.539682,"median":-1.259605,"eighty":-0.638616,"marketCap":36332127},{"date":"2025-06-27","current":-0.524276,"twenty":-1.524863,"median":-1.24849,"eighty":-0.622528,"marketCap":32122917},{"date":"2025-07-03","current":-0.54597,"twenty":-1.518935,"median":-0.809312,"eighty":-0.609134,"marketCap":33452141},{"date":"2025-07-11","current":-0.535123,"twenty":-1.515971,"median":-0.771713,"eighty":-0.598047,"marketCap":32787529},{"date":"2025-07-18","current":-0.506198,"twenty":-1.508562,"median":-0.726755,"eighty":-0.578462,"marketCap":31015230},{"date":"2025-07-25","current":-0.513429,"twenty":-1.504116,"median":-0.717873,"eighty":-0.562281,"marketCap":31458305},{"date":"2025-08-01","current":-0.421229,"twenty":-1.501152,"median":-0.708677,"eighty":-0.556817,"marketCap":25809102},{"date":"2025-08-06","current":-0.443838,"twenty":-1.496707,"median":-0.705061,"eighty":-0.54597,"marketCap":27194422}],"updateTime":1754567847184}}}